RemeGen Management
Management criteria checks 3/4
RemeGen's CEO is Jianmin Fang, appointed in Oct 2008, has a tenure of 15.75 years. total yearly compensation is CN¥14.66M, comprised of 37% salary and 63% bonuses, including company stock and options. directly owns 11.44% of the company’s shares, worth HK$2.40B. The average tenure of the management team and the board of directors is 2.5 years and 4.2 years respectively.
Key information
Jianmin Fang
Chief executive officer
CN¥14.7m
Total compensation
| CEO salary percentage | 37.0% |
| CEO tenure | 15.8yrs |
| CEO ownership | 11.4% |
| Management average tenure | 2.5yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet
Jun 21
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up
Apr 04Is RemeGen (HKG:9995) Using Debt In A Risky Way?
Mar 24RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Feb 18Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely
Dec 29RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate
Oct 16Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?
Aug 03Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?
Jun 22RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected
May 10Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?
Mar 09RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear
May 04RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially
Apr 08RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates
Feb 23We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely
Jan 21Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?
Nov 30We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely
Oct 16A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)
Aug 24Here's What RemeGen Co., Ltd.'s (HKG:9995) Shareholder Ownership Structure Looks Like
Feb 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -CN¥2b |
| Dec 31 2023 | CN¥15m | CN¥5m | -CN¥2b |
| Sep 30 2023 | n/a | n/a | -CN¥1b |
| Jun 30 2023 | n/a | n/a | -CN¥1b |
| Mar 31 2023 | n/a | n/a | -CN¥1b |
| Dec 31 2022 | CN¥27m | CN¥5m | -CN¥999m |
| Sep 30 2022 | n/a | n/a | CN¥276m |
| Jun 30 2022 | n/a | n/a | CN¥231m |
| Mar 31 2022 | n/a | n/a | CN¥174m |
| Dec 31 2021 | CN¥8m | CN¥4m | CN¥276m |
Compensation vs Market: Jianmin's total compensation ($USD2.02M) is above average for companies of similar size in the Hong Kong market ($USD446.28K).
Compensation vs Earnings: Jianmin's compensation has been consistent with company performance over the past year.
CEO
Jianmin Fang (61 yo)
15.8yrs
Tenure
CN¥14,658,000
Compensation
Dr. Jianmin Fang is Co-Founder at RemeGen Co. Ltd. He has been Director, Chief Executive Officer and served as Chief Scientific Officer of RemeGen Co. Ltd. since October 16, 2008 to 2023 and redesignated a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.8yrs | CN¥14.66m | 11.44% CN¥ 2.4b | |
| Chief Medical Officer | no data | CN¥24.01m | 0.074% CN¥ 15.6m | |
| Executive Director | no data | CN¥1.13m | no data | |
| CFO & Joint Company Secretary | less than a year | no data | no data | |
| Chief Operating Officer | no data | no data | no data | |
| Chief Technical Officer | no data | no data | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Chief Manufacturing Officer | no data | no data | no data | |
| Joint Company Secretary | 4.2yrs | no data | no data |
2.5yrs
Average Tenure
61yo
Average Age
Experienced Management: 9995's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.8yrs | CN¥14.66m | 11.44% CN¥ 2.4b | |
| Chief Medical Officer | 4.2yrs | CN¥24.01m | 0.074% CN¥ 15.6m | |
| Executive Director | 16yrs | CN¥1.13m | no data | |
| Member of Scientific Advisory Board | no data | CN¥125.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Executive Chairman | 10.8yrs | CN¥15.15m | no data | |
| Non-Executive Director | 4.2yrs | no data | 4.69% CN¥ 982.8m | |
| Non-Executive Director | 4.2yrs | no data | no data | |
| Independent Non-Executive Director | 4.2yrs | CN¥300.00k | no data | |
| Chairman of the Supervisory Committee | 4.2yrs | no data | no data | |
| Independent Non-Executive Director | 3.1yrs | CN¥300.00k | no data | |
| Independent Non-Executive Director | 2.2yrs | CN¥300.00k | no data |
4.2yrs
Average Tenure
61yo
Average Age
Experienced Board: 9995's board of directors are considered experienced (4.2 years average tenure).